scottalban_astrazeneca
12 July 2018Americas

LSIPR 50 2018: Leading the transformation change

Charged with protecting the innovation arising from MedImmune, the global biologics research and development arm of AstraZeneca, as well as AstraZeneca’s innovative medicines and early development biotech units, Scott Alban’s job is far from insignificant.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
7 April 2026   According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.
Americas
1 April 2026   After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.
Americas
30 March 2026   A long-running patent clash over gene editing returns to a fundamental question, as a US court takes another look at the evidence.